Experience of teicoplanin use for outpatient parenteral antibiotic therapy treatment
Abstract:
Teicoplanin is a glycopeptide antibiotic with a long elimination half-life (50 hours) that allows administration thrice a week, though it is approved for daily use. The aim of this retrospective, single-arm study is to assess the clinical outcome of using thrice-weekly teicoplanin (TWT) as outpatient parenteral antibiotic therapy (OPAT) for deep (DSIs) and non-deep-seated infections (NDSIs). We included 37 outpatients (25 with DSIs and 12 with NDSIs) treated with TWT between 01/2021 and 10/2023. The outcome was favorable in 78% of them (80% with DSI, 75% with NDSIs) and Therapeutic drug monitoring (TDM) was performed in all cases. 8 patients required dosage modification because of inadequate trough levels; they were younger and had a higher creatinine clearance. 6/37 patients experienced adverse events, mostly skin rash (4/6). TWT can be a good option for OPAT; its pharmacokinetic reduces the number of hospital accesses and TDM permits to tailor the dosage.
Reference:
Morena V, Conti F, Cattaneo D, Trentacapilli B, Bottanelli M, Bradanini L, Chiesa A, Gemignani N, Molteni C, Pandolfo A, Volpi S, Consonni A, Valesecchi G, Pontiggia S, Piconi S. Thrice-weekly teicoplanin: an old drug for modern needs. Experience of its use as outpatient parenteral antibiotic therapy (OPAT) at infectious disease unit of Manzoni hospital (Lecco). J Chemother. 2025 Oct 22:1-8. doi: 10.1080/1120009X.2025.2575226. Epub ahead of print. PMID: 41123236.